Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Administration of minocycline Clear all
Terminated Phase 1 Interventional

The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization

NCT02178813
View directory record Official record
Conditions
Stroke
Interventions
Administration of minocycline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 3 Interventional

Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis

NCT00371332
View directory record Official record
Conditions
Periodontitis
Interventions
Minocycline HCL Microspheres
Drug
Lead sponsor
OraPharma
Industry
Eligibility
30 Years to 65 Years
Enrollment
128 participants
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2006 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133872
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline 50mg/d, Minocycline 100mg/d, Minocycline 200mg/d
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

NCT02203552
View directory record Official record
Conditions
Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 2, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Results available

Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults

NCT00361257
View directory record Official record
Conditions
HIV Infections
Interventions
Minocycline, Placebo (Tetracycline)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 4 Interventional

A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris

NCT04940767
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin, Amzeeq 4% Topical Foam
Drug
Lead sponsor
Edward Lain, MD
Network
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Dripping Springs, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815267
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Birmingham, Alabama • Fremont, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg

NCT03762915
View directory record Official record
Conditions
SRP, Minocycline HCl Microspheres, Biomarkers
Interventions
minocycline HCl microspheres
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 2, 2026, 2:26 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

NCT02133885
View directory record Official record
Conditions
Hypertension
Interventions
Minocycline Group, Placebo Group
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration

NCT02564978
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Minocycline
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 2, 2026, 2:26 AM EDT
Terminated Phase 2 Interventional Results available

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

NCT01349192
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline, Mupirocin, chlorhexidine gluconate oral rinse, 2% Chlorhexidine solution wipes, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 2, 2026, 2:26 AM EDT
Not listed Not applicable Interventional

Supplemental Adjuvants for Intracellular Nutrition and Treatment

NCT00893724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

NCT03050086
View directory record Official record
Conditions
Moderate to Severe Papulopustular Rosacea
Interventions
BPX-04 1% minocycline topical gel, BPX-04 2% minocycline topical gel, BPX-04 vehicle topical gel
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 2, 2026, 2:26 AM EDT
Terminated Not applicable Interventional Results available

Enoxaparin and/or Minocycline in Acute Stroke

NCT00836355
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Enoxaparin, Minocycline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 2, 2026, 2:26 AM EDT
Completed No phase listed Observational

Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia

NCT06112938
View directory record Official record
Conditions
Stenotrophomonas Maltophilia Infection
Interventions
Antibiotic
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 2, 2026, 2:26 AM EDT
Not listed Phase 3 Interventional

Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study

NCT00203697
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
minocycline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
20 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 2, 2026, 2:26 AM EDT
Completed No phase listed Observational

A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting

NCT03160040
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Minocycline IV
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste

NCT00881491
View directory record Official record
Conditions
Pulp Necrosis
Interventions
Double Antibiotic Paste, Triple Antibiotic Paste, Mineral Trioxide Aggregate
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
7 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

NCT02946788
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Minocycline
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Coral Gables, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Glendale, Arizona • Rogers, Arkansas • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 2, 2026, 2:26 AM EDT
Recruiting Phase 2Phase 3 Interventional

Minocycline in Stroke Study at Maimonides

NCT07237048
View directory record Official record
Conditions
Stroke, Ischemia Stroke, Hemorrhagic Strokes, Mortality, Morbidity, Cerebrovascular Accident (Stroke), Intracerebral Haemorrhage (ICH)
Interventions
Minocycline 200mg
Drug
Lead sponsor
Joyce Chen
Other
Eligibility
18 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea

NCT05014906
View directory record Official record
Conditions
Rosacea
Interventions
Minocycline 45 MG, Azelaic acid
Drug
Lead sponsor
Dermatology Specialists Research
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 2, 2026, 2:26 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)

NCT01058395
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Minocycline
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Dearborn, Michigan • Trenton, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 2, 2026, 2:26 AM EDT